Indication
Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (?-galactosidase A deficiency) and who have an amenable mutation.
Loading your page…
Loading your page…
Fabry Disease
Marketing Authorisation Holder: Amicus Therapeutics Europe Limited
EMA Authorisation: 25/05/2016
INN: migalastat
AI Drug & Interaction Analysis
Free account required
Ask Osler about Galafold: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.